| Humanization of an anti-p185HER2 antibody for human cancer therapy. P Carter, LEN Presta, CM Gorman, JB Ridgway, D Henner, WL Wong, ... Proceedings of the National Academy of Sciences 89 (10), 4285-4289, 1992 | 3073 | 1992 |
| Potent antibody therapeutics by design PJ Carter Nature reviews immunology 6 (5), 343-357, 2006 | 1687 | 2006 |
| Hydrogen bonding and biological specificity analysed by protein engineering AR Fersht, JP Shi, J Knill-Jones, DM Lowe, AJ Wilkinson, DM Blow, ... Nature 314 (6008), 235-238, 1985 | 1342 | 1985 |
| Improving the efficacy of antibody-based cancer therapies P Carter Nature Reviews Cancer 1 (2), 118-129, 2001 | 1337 | 2001 |
| Therapeutic antibodies for autoimmunity and inflammation AC Chan, PJ Carter Nature reviews immunology 10 (5), 301-316, 2010 | 1171 | 2010 |
| ‘Knobs-into-holes’ engineering of antibody CH3 domains for heavy chain heterodimerization JBB Ridgway, LG Presta, P Carter Protein Engineering, Design and Selection 9 (7), 617-621, 1996 | 1114 | 1996 |
| Dissecting the catalytic triad of a serine protease P Carter, JA Wells Nature 332 (6164), 564-568, 1988 | 876 | 1988 |
| An efficient route to human bispecific IgG AM Merchant, Z Zhu, JQ Yuan, A Goddard, CW Adams, LG Presta, ... Nature biotechnology 16 (7), 677-681, 1998 | 846 | 1998 |
| Improved oligonudeotide site-directed rautagenesis using M13 vectors P Carter, H Bedouelle, G Winter Nucleic Acids Research 13 (12), 4431-4443, 1985 | 804 | 1985 |
| Alternative molecular formats and therapeutic applications for bispecific antibodies C Spiess, Q Zhai, PJ Carter Molecular immunology 67 (2), 95-106, 2015 | 744 | 2015 |
| The use of double mutants to detect structural changes in the active site of the tyrosyl-tRNA synthetase (Bacillus stearothermophilus) PJ Carter, G Winter, AJ Wilkinson, AR Fersht Cell 38 (3), 835-840, 1984 | 712 | 1984 |
| Next generation antibody drugs: pursuit of the 'high-hanging fruit' GA Carter, P. J. and Lazar Nature Reviews Drug Discovery 17, 197-223, 2018 | 707 | 2018 |
| Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies GD Lewis, I Figari, B Fendly, W Lee Wong, P Carter, C Gorman, ... Cancer Immunology, Immunotherapy 37, 255-263, 1993 | 698 | 1993 |
| Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro D Kirpotin, JW Park, K Hong, S Zalipsky, WL Li, P Carter, CC Benz, ... Biochemistry 36 (1), 66-75, 1997 | 640 | 1997 |
| High Level Escherichia coli Expression and Production of a Bivalent Humanized Antibody Fragment P Carter, RF Kelley, ML Rodrigues, B Snedecor, M Covarrubias, ... Bio/technology 10 (2), 163-167, 1992 | 633 | 1992 |
| Introduction to current and future protein therapeutics: a protein engineering perspective PJ Carter Experimental cell research 317 (9), 1261-1269, 2011 | 620 | 2011 |
| Antibody-drug conjugates for cancer therapy PJ Carter, PD Senter The Cancer Journal 14 (3), 154-169, 2008 | 521 | 2008 |
| Site-directed mutagenesis. P Carter Biochemical Journal 237 (1), 1, 1986 | 489 | 1986 |
| Development of anti-p185HER2 immunoliposomes for cancer therapy. JW Park, K Hong, P Carter, H Asgari, LY Guo, GA Keller, C Wirth, ... Proceedings of the National Academy of Sciences 92 (5), 1327-1331, 1995 | 484 | 1995 |
| Bispecific human IgG by design P Carter Journal of immunological methods 248 (1-2), 7-15, 2001 | 398 | 2001 |
Alan FershtEmeritus Group Leader, MRC Laboratory of Molecular Biology, University of Cambridge在 cam.ac.uk 的电子邮件经过验证
